Jun 22, 2021 / 12:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the SY-1425 for newly diagnosed and unfit acute myeloid leukemia conference call.
(Operator Instructions)
As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Nancy Simonian, Chief Executive Officer of Syros Pharmaceuticals. Please, go ahead.
Nancy A. Simonian - Syros Pharmaceuticals, Inc. - President, CEO, Interim Principal Financial & Accounting Officer and Director
Great. Thank you, operator. Good morning, and welcome to our KOL event on SY-1425 in newly diagnosed unfit AML.
We will be making forward-looking statements. A full description of our risk factors can be found on our website. This is the second of a 3-part series of KOL events on our targeted hematology portfolio.
We are very pleased to have Dr. Daniel Pollyea, the Associate Professor of Medicine, Clinical Director of the Leukemia Services and the Robert H. Allen Chair in Hematology Research at the University of Colorado School of Medicine as our
Syros Pharmaceuticals Inc SY-1425 in Newly Diagnosed Unfit AML-Call Transcript
Jun 22, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers